Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Integrated process optimization: lessons from retrovirus and virus-like particle production.

P E Cruz1, L Maranga, M J T Carrondo

  • 1IBET/ITQB, Apartado 12, P-2780 Oeiras, Portugal.

Journal of Biotechnology
|October 19, 2002
PubMed
Summary

This study introduces a novel optimization model for biopharmaceutical production, integrating biological and technological factors. The model enhances bioprocess development for complex biologics like virus-like particles (VLPs) and retroviruses.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

LentiPro26: novel stable cell lines for constitutive lentiviral vector production.

Scientific reports·2018
Same author

In vitro expansion of human cardiac progenitor cells: exploring 'omics tools for characterization of cell-based allogeneic products.

Translational research : the journal of laboratory and clinical medicine·2016
Same author

Tetraspanins displayed in retrovirus-derived virus-like particles and their immunogenicity.

Vaccine·2016
Same author

What Makes Umbilical Cord Tissue-Derived Mesenchymal Stromal Cells Superior Immunomodulators When Compared to Bone Marrow Derived Mesenchymal Stromal Cells?

Stem cells international·2015
Same author

Down-regulation of CD81 tetraspanin in human cells producing retroviral-based particles: tailoring vector composition.

Biotechnology and bioengineering·2011
Same author

Synchronous fluorescence spectroscopy as a novel tool to enable PAT applications in bioprocesses.

Biotechnology and bioengineering·2011

Area of Science:

  • Biotechnology and Bioprocess Engineering
  • Biopharmaceutical Process Development
  • Molecular Virology

Background:

  • Traditional bioprocess optimization often overlooks the interplay between biological and technological aspects.
  • Complex biologics, including virus-like particles (VLPs) and retroviruses, require integrated optimization strategies for efficient production and purification.
  • Existing models may not fully capture the multifaceted challenges in scaling up biopharmaceutical manufacturing.

Purpose of the Study:

  • To define and apply a comprehensive optimization model for biopharmaceutical production processes.
  • To integrate both biological and technological considerations into optimization protocols.
  • To systematically evaluate and improve the production of specific bioparticles, such as human immunodeficiency virus 1 (HIV-1) and porcine parvovirus (PPV) VLPs, and retroviruses.

Related Experiment Videos

Main Methods:

  • Development of a four-level optimization framework: product, technology, design, and integration.
  • Application of the model to three distinct bioproduction systems: HIV-1 VLPs in insect cells, PPV VLPs in insect cells, and retroviruses in mammalian cells.
  • Analysis of optimization limits and decision-making points for each level within the studied systems.

Main Results:

  • Demonstrated the applicability of the integrated optimization model across diverse bioproduction systems.
  • Identified critical decision points for enhancing VLP and retrovirus production.
  • Provided insights into the limitations and strengths of each optimization level.

Conclusions:

  • The proposed integrated optimization model offers a universal approach for developing complex biopharmaceutical processes.
  • This strategy facilitates informed decisions in production and purification, leading to improved bioprocess development.
  • The model's adaptability supports the advancement of manufacturing for advanced therapeutics and vaccines.